For two decades, Medicare’s answer to obesity drugs was simple: by law, its prescription drug benefit generally did not pay for medication used specifically for weight loss. That changed in July 2026, when a temporary federal demonstration began providing selected GLP-1 treatments to qualifying Medicare beneficiaries. A new analysis presented at ObesityWeek 2026 shows how large the older population on the other side of that decision has become.
The estimated number of Medicare beneficiaries aged 65 and older with obesity rose from 9.7 million to 24.6 million between 1999–2000 and 2021–2023, according to research by Muntner and colleagues summarized by AJMC on November 14. Severe obesity grew faster still. The figures describe a population whose health needs are expanding just as Medicare begins testing broader access to weight-loss medications.
That is not a projection of future obesity or a count of patients eligible for the new drug program. It is an estimate drawn from the National Health and Nutrition Examination Survey, or NHANES, the federal government’s long-running health survey that measures height and weight rather than relying only on self-reports. The analysis included 14,916 adults aged 65 and older who reported Medicare coverage.
The difference between having obesity and qualifying for coverage matters. Medicare’s new GLP-1 Bridge is not an open prescription benefit for everyone with a high body mass index. It has specific medical requirements, covers only certain products and is currently scheduled to end in December 2027.
The Medicare GLP-1 Coverage Math Starts With Prevalence
Two forces are behind the jump. The share of older Medicare beneficiaries with obesity rose from 33.6% to 40.5%, and the older Medicare population itself grew as the baby boom generation aged. The estimated total number of beneficiaries aged 65 and over increased from 28.8 million to 60.9 million across the study periods. Combine greater prevalence with a much larger population and the absolute number with obesity more than doubles.
Severe obesity, defined as a body mass index of at least 40, rose from approximately 1.3 million people, or 4.5% of beneficiaries, to 4.5 million, or 7.4%. The researchers also found that the estimated annual increase in beneficiaries with obesity accelerated after the 2013–2014 survey cycle.
The study showed that obesity in older adults travels with expensive medical conditions. Diabetes affected 40.2% of those with obesity and 53.0% of those with severe obesity, compared with 19.4% of beneficiaries without obesity. Metabolic dysfunction-associated steatohepatitis, the liver condition known as MASH, followed a similar pattern.
Heart failure was especially uneven. It affected 23.3% of beneficiaries with severe obesity, compared with 11.4% of those with obesity overall and 6.2% of those without obesity. These are conditions that already put pressure on Medicare spending, although their presence does not automatically make someone eligible for treatment through the GLP-1 Bridge.
Medicare’s older obesity population did not creep up. It more than doubled, and the severe end grew fastest.
The scale explains why drug coverage is becoming a significant financial question. It does not, by itself, tell policymakers how many prescriptions Medicare will ultimately pay for.
What Medicare Agreed to Pay
The coverage grew out of drug-pricing agreements announced in November 2025 involving the federal government, Eli Lilly and Novo Nordisk. Under the Medicare GLP-1 Bridge, which began July 1, 2026, participating manufacturers provide eligible medications at a net price of $245 per monthly supply. Qualifying beneficiaries pay a fixed $50 monthly copayment.
There is an important difference between that agreement and the actual list of covered medicines. The broader 2025 pricing announcement discussed Ozempic, Wegovy, Mounjaro and Zepbound. The Bridge’s weight-management product list is narrower: Foundayo tablets, Wegovy injections or tablets, and Zepbound in the KwikPen formulation. Other formulations and drugs are not automatically covered for obesity through this demonstration.
Eligibility is narrower than the national obesity count too. Beneficiaries generally need qualifying Medicare Part D coverage and must meet one of several clinical thresholds. Those include a BMI of at least 35; a BMI of at least 30 with certain conditions such as uncontrolled hypertension, heart failure with preserved ejection fraction or advanced chronic kidney disease; or a BMI of at least 27 with specified conditions such as prediabetes or a previous heart attack or stroke.
Prescribers must submit a prescription and obtain prior authorization. Patients also must satisfy additional program requirements. People who already receive GLP-1 coverage through Part D, or have certain diagnoses for which GLP-1 drugs are covered under the regular Part D benefit, are excluded from the Bridge and must use the applicable Part D process instead.

The Bridge is also separate from the ordinary Part D payment system. The $50 copayment does not count toward a patient’s Part D deductible or annual out-of-pocket spending cap, and the usual Part D low-income cost-sharing subsidies do not apply. That means a $50 price can still be a barrier for people with limited incomes.
A separate analysis from KFF offers a more realistic indication of the eligible population than the 24.6 million obesity figure. Using 2023 Medicare claims data, KFF estimated that approximately 3.8 million beneficiaries met the Bridge’s eligibility requirements. The two estimates use different methods and populations, so they should not be treated as a direct subtraction. But the distinction is decisive: the potential coverage population is much smaller than the total burden of obesity.
Will the Drugs Offset Their Cost?
The argument for expanding obesity treatment is that better health outcomes may reduce spending on heart attacks, hospitalizations, diabetes complications and other expensive conditions. The difficulty is showing whether those savings are large enough to offset the ongoing cost of the medicines.
A second ObesityWeek analysis, by Cai and colleagues using Optum Market Clarity data, offers a partial look. Among 27,013 commercially insured adults with obesity or overweight who started injectable semaglutide or tirzepatide, those who stayed on their initial treatment for at least a year had adjusted medical costs $1,422 to $2,400 lower over the following six months than groups who stopped treatment earlier. Persistent users also had fewer emergency department visits and hospital admissions.
Three caveats keep that from settling the Medicare question. Only 41.9% of the patients stayed on treatment for at least 12 months. The cost analysis excluded pharmacy spending, which is the major additional expense when someone starts a GLP-1. And the patients were commercially insured adults, not a Medicare-specific population. The results were observational, so differences between those who continued treatment and those who stopped may not be fully explained by the drug itself.
The AJMC roundup also noted that the observational analyses presented included coauthors affiliated with Amgen, which is developing its own obesity medicine. That does not negate the findings, but the research is not the independent, Medicare-specific cost-offset evidence needed to settle the spending question.
A lower unit price multiplied by a very large treated population is still a large bill. Lower medical spending does not automatically mean lower total spending.
KFF has modeled the federal cost under different levels of participation. Using its estimated 3.8 million eligible beneficiaries, it calculated that 10% to 25% participation, with regular monthly prescriptions across the demonstration, would cost Medicare roughly $1.3 billion to $3.3 billion over 18 months. Those are scenarios, not observed expenditures. They show how much the budget depends on uptake, treatment duration and the number of prescriptions actually filled.
Where This Collides With Drug Price Negotiation
Medicare has another price lever operating alongside the Bridge. Semaglutide products including Ozempic, Rybelsus and Wegovy were selected for the Medicare Drug Price Negotiation Program, with negotiated maximum fair prices scheduled to take effect in 2027 for applicable Part D uses.
The two price mechanisms should not be treated as interchangeable. The Bridge is a temporary demonstration that uses a separate payment process for eligible weight-management prescriptions. Medicare’s Drug Price Negotiation Program governs selected drugs within the statutory Medicare drug-pricing framework. Which payment arrangement applies depends on the drug, indication and coverage pathway.
CMS also issued a final negotiation rule on November 5, 2026, codifying provisions for the program’s later years. Grey Pepper examined the details in its report on Medicare’s drug price negotiation final rule.
There is a second uncertainty. The Medicare GLP-1 Bridge was originally intended to lead into a different coverage model called BALANCE. But the planned 2027 Medicare Part D launch of BALANCE was delayed, and the Bridge was extended through December 31, 2027. What happens to beneficiaries receiving obesity treatment after that date depends on future coverage decisions.
The Access Problem Has Not Disappeared
The new prevalence data cannot tell us how many beneficiaries currently meet the Bridge’s clinical rules, how many want treatment, how many receive approval or how long they will remain on therapy. It also ends with the 2021–2023 survey period, before the current Medicare demonstration began.
Commercial insurance offers a cautionary comparison. A separate ObesityWeek analysis of telehealth-linked insurance data found that 35.7% of 69,462 initial prior authorization submissions for GLP-1 weight-management therapy were denied. The most common reasons included plan exclusions, unmet clinical criteria and treatment requirements such as trying another medication first.
Those figures came from commercially insured adults aged 18 to 63, not Medicare beneficiaries. They cannot be used as an estimate of the Bridge’s denial rate. But they illustrate how an approved drug and an insurance benefit can still be separated from a patient by administrative rules.
Grey Pepper has also examined this problem in its coverage of the Medicare GLP-1 Bridge enrollment gap. Approval, enrollment, prescription filling and sustained treatment are different stages of access. A large eligible population does not guarantee equivalent real-world use.
What Medicare’s New Obesity Numbers Really Mean
The ObesityWeek research establishes the scale of an underlying health problem. About four in ten Medicare beneficiaries aged 65 and older had obesity in the latest NHANES period examined, and severe obesity became substantially more common. Diabetes, liver disease and heart failure were also more prevalent among those with obesity than among their peers without it.
But prevalence is not eligibility. Eligibility is not enrollment. Enrollment is not continued treatment. And continued treatment is not proof that the savings from avoiding future illness exceed the price of the drug.
The Medicare GLP-1 Bridge is an attempt to test some of those questions under a lower-price arrangement. CMS can examine real-world access, utilization and spending during the demonstration, though determining long-term health outcomes and net budget effects will require more evidence than an 18-month payment experiment alone can provide.
What is already clear is the size of the population whose needs have changed. Medicare did not create the obesity burden when it began paying for selected GLP-1 drugs. That burden had been growing for decades. The program now faces the harder question: how much treatment can it provide, to whom, and at what lasting cost?
Sources
- AJMC — ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity’s Costs. November 14, 2026. Reports the Muntner prevalence study, Cai persistence analysis and commercial coverage research.
- Centers for Medicare & Medicaid Services — Medicare GLP-1 Bridge. Official program description, dates and copayment policy.
- Medicare.gov — Weight Loss Drugs. Covered products, beneficiary eligibility and prior authorization requirements.
- CMS — Information for Part D Plans. Program payment structure, $245 net price and distinction from regular Part D coverage.
- KFF — Nearly Four Million Medicare Beneficiaries Could Be Eligible for the Temporary Medicare GLP-1 Bridge Program. June 29, 2026. Claims-based eligibility estimates and modeled federal costs.
- Becker’s Hospital Review — Medicare to Cover GLP-1s Under Trump-Negotiated Pricing. November 6, 2025.
- CMS — Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Final Rule. November 5, 2026.

